title: Toll-like receptors in urothelial cells--targets for cancer immunotherapy.
abstract: Toll-like receptors (TLRs) have an important role in the activation of both innate and adaptive immunity in response to pathogens and danger signals. These receptors are expressed in immune cells and in some epithelia. They are expressed in the epithelium of the urinary bladder, where they actively participate in the fight against infection by uropathogens. TLR expression is decreased (although still evident) in bladder tumours, especially in non-muscle-invasive tumours. Intravesical immunotherapy with BCG to prevent recurrence of these tumours has been shown to involve the participation of three different TLRs (TLR2, TLR4, and TLR9). However, alternative therapies are needed as BCG fails in some patients and can sometimes cause severe adverse effects that are difficult to tolerate. In recent years, TLR2, TLR4, TLR7, and TLR9 agonists have been tested in vitro and in vivo for their ability to activate an antitumour immune response against bladder cancer. Promising results from these studies have led to the testing of TLR7 and TLR9 agonists in clinical trials.
authors: Centre de Recherche en Cancérologie de l'Université Laval, CHU de Québec-L'Hôtel-Dieu de Québec, 10 McMahon, Québec, QC G1R 3S1, Canada.
authors: Hélène
authors: H
authors: LaRue
authors: Cherifa
authors: C
authors: Ayari
authors: Alain
authors: A
authors: Bergeron
authors: Yves
authors: Y
authors: Fradet
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000378:metabolism*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051193:Toll-Like Receptors / Q000378:metabolism* / Q000502:physiology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism*; D019459:Urothelium / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D051193:Toll-Like Receptors
references: J Immunol. 2006 Sep 1;177(5):3162-9
references: 16920954
references: J Urol. 2011 May;185(5):1915-21
references: 21421234
references: Cell Microbiol. 2005 Apr;7(4):591-601
references: 15760459
references: Infect Immun. 1984 Dec;46(3):839-44
references: 6389367
references: Science. 2004 Mar 5;303(5663):1522-6
references: 15001781
references: Eur Urol. 2011 Jun;59(6):997-1008
references: 21458150
references: J Endotoxin Res. 2007;13(1):6-14
references: 17621541
references: J Immunol. 1987 May 15;138(10):3475-80
references: 3553327
references: Eur Urol. 2009 Aug;56(2):247-56
references: 19409692
references: Nat Rev Immunol. 2003 Feb;3(2):133-46
references: 12563297
references: Cancer Immunol Immunother. 2012 Jan;61(1):31-40
references: 21833592
references: Cytokine. 2010 Jan;49(1):1-9
references: 19775907
references: Oncogene. 2008 Jan 7;27(2):225-33
references: 18176604
references: Gastroenterol Res Pract. 2010;2010:240365
references: 21197425
references: Br J Cancer. 2003 Dec 15;89(12):2312-9
references: 14676812
references: Infect Dis Clin North Am. 1997 Sep;11(3):551-81
references: 9378923
references: Infect Immun. 2004 Apr;72(4):2400-4
references: 15039368
references: Curr Opin Microbiol. 2008 Feb;11(1):66-73
references: 18243043
references: Cancer Immunol Immunother. 2011 Sep;60(9):1211-20
references: 21789594
references: Pharmacoeconomics. 2003;21(18):1315-30
references: 14750899
references: Infect Immun. 2000 Dec;68(12):6883-90
references: 11083809
references: Urol Oncol. 2008 Jul-Aug;26(4):341-5
references: 18593617
references: Eur Urol. 2011 Jun;59(6):978-84
references: 21257257
references: J Infect Dis. 2002 Nov 15;186(10):1522-5
references: 12404174
references: Anticancer Res. 2010 Oct;30(10):4089-96
references: 21036724
references: J Urol. 1990 Jul;144(1):53-8
references: 2359181
references: Int J Cancer. 1997 Jun 11;71(6):986-92
references: 9185702
references: Immunobiology. 2008;213(3-4):205-24
references: 18406368
references: EMBO Rep. 2004 Oct;5(10):1000-6
references: 15359270
references: J Urol. 2003 Sep;170(3):964-9
references: 12913751
references: J Immunol. 2007 Apr 15;178(8):4717-20
references: 17404249
references: Nature. 2000 Dec 7;408(6813):740-5
references: 11130078
references: Cancer Invest. 2008 Oct;26(8):816-21
references: 18608206
references: Cancer Res. 2006 Aug 15;66(16):8250-7
references: 16912205
references: Anticancer Res. 2004 Jul-Aug;24(4):2225-30
references: 15330165
references: J Urol. 2013 Jun;189(6):2077-82
references: 23206424
references: Pediatr Res. 2007 Mar;61(3):371-4
references: 17314700
references: Target Oncol. 2012 Mar;7(1):29-54
references: 22399234
references: Cancer Sci. 2010 Jul;101(7):1596-603
references: 20507323
references: J Immunother. 2010 Apr;33(3):225-35
references: 20445343
references: J Immunol. 2010 Aug 15;185(4):2405-15
references: 20660347
references: Vaccine. 2006 Jul 26;24(31-32):5862-71
references: 16725239
references: J Urol. 2011 Sep;186(3):1084-92
references: 21784459
references: PLoS One. 2009 Jun 22;4(6):e5990
references: 19543401
references: J Clin Invest. 1990 Jan;85(1):62-7
references: 2404029
references: mBio. 2011 May 31;2(3):e00094-11
references: 21628500
references: Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13766-71
references: 11095740
references: Expert Opin Investig Drugs. 2008 Jul;17(7):1067-73
references: 18549342
references: Eur Urol. 2009 Sep;56(3):430-42
references: 19576682
references: Curr Opin Immunol. 2011 Aug;23(4):464-72
references: 21726990
references: Nat Immunol. 2010 May;11(5):373-84
references: 20404851
references: J Leukoc Biol. 2003 Aug;74(2):277-86
references: 12885945
references: J Urol. 2009 Mar;181(3):1040-5
references: 19150551
references: Nature. 2001 Apr 26;410(6832):1099-103
references: 11323673
references: Curr Opin Microbiol. 2006 Feb;9(1):33-9
references: 16406777
references: Br J Cancer. 1999 Jan;79(2):229-35
references: 9888462
references: J Microbiol Methods. 2009 May;77(2):139-44
references: 19318051
references: Clin Cancer Res. 2007 Oct 1;13(19):5703-9
references: 17908959
references: Kidney Int. 2007 Apr;71(8):721-3
references: 17429419
references: Int J Biol Sci. 2010 Nov 03;6(7):675-81
references: 21060729
references: Oncoimmunology. 2012 Sep 1;1(6):894-907
references: 23162757
references: Biomed Pharmacother. 2007 Jul;61(6):299-305
references: 17604943
references: Cancer Immunol Immunother. 2009 Sep;58(9):1375-85
references: 19184006
references: J Physiol Pharmacol. 2009 May;60 Suppl 1:65-71
references: 19609015
references: Cell Host Microbe. 2007 Jun 14;1(4):287-98
references: 17710226
references: Immunobiology. 2006;211(6-8):557-65
references: 16920494
references: Arch Med Res. 2013 Jan;44(1):54-61
references: 23142523
references: Immunity. 2011 May 27;34(5):637-50
references: 21616434
references: Clin Cancer Res. 2000 Feb;6(2):397-405
references: 10690516
references: J Urol. 2011 Dec;186(6):2158-67
references: 22014799
references: Clin Diagn Lab Immunol. 2004 Sep;11(5):969-76
references: 15358661
references: Infect Immun. 2003 Aug;71(8):4647-56
references: 12874345
references: Nat Immunol. 2003 Dec;4(12):1247-53
references: 14625549
references: J Urol. 2005 Sep;174(3):1119-23
references: 16094077
references: Arch Med Res. 2008 Jan;39(1):33-9
references: 18067993
references: Cell. 2006 Feb 24;124(4):783-801
references: 16497588
references: Cancer Sci. 2008 Jul;99(7):1435-40
references: 18452561
references: J Immunother. 2008 Jan;31(1):34-42
references: 18157010
references: Anticancer Res. 2009 Jun;29(6):2067-76
references: 19528466
references: J Urol. 1995 Aug;154(2 Pt 1):572-5
references: 7609139
references: J Immunol. 2001 Oct 1;167(7):3555-8
references: 11564765
references: Urol Res. 1993;21(5):349-52
references: 8279092
references: J Urol. 2007 Jun;177(6):2347-51
references: 17509356
references: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references: 18287387
references: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4565-74
references: 17671143
references: Arch Pharm Res. 2012 Aug;35(8):1297-316
references: 22941474
references: Cancer Res. 1991 Jul 15;51(14):3726-32
references: 2065329
references: Eur J Clin Invest. 2008 Oct;38 Suppl 2:21-8
references: 18826478
references: J Clin Oncol. 1995 Jun;13(6):1404-8
references: 7751885
references: Nat Immunol. 2002 Jul;3(7):667-72
references: 12055629
references: Tumour Biol. 2005 Sep-Oct;26(5):274-80
references: 16103747
references: J Immunother. 2005 Jan-Feb;28(1):20-7
references: 15614041
references: Vascul Pharmacol. 2006 Oct;45(4):221-6
references: 16891158
references: Microbes Infect. 2003 Oct;5(12):1070-81
references: 14554248
references: J Infect Dis. 2007 Aug 1;196(3):475-84
references: 17597463
references: Expert Opin Investig Drugs. 2001 Dec;10(12):2157-65
references: 11772311
references: J Cancer Res Clin Oncol. 2009 Mar;135(3):379-86
references: 18825409
references: Pathol Oncol Res. 2013 Apr;19(2):275-80
references: 23065466
references: Int J Urol. 2010 May;17(5):483-90
references: 20337728
references: Am J Physiol Renal Physiol. 2009 Dec;297(6):F1477-501
references: 19587142
references: Infect Immun. 2003 Mar;71(3):1470-80
references: 12595465
references: Hum Immunol. 2011 Nov;72(11):1095-116
references: 21872627
references: Nat Rev Drug Discov. 2010 Apr;9(4):293-307
references: 20380038
references: PLoS One. 2009 Dec 15;4(12):e8300
references: 20016852
references: Eur J Immunol. 2006 Feb;36(2):267-77
references: 16385628
references: BJU Int. 2006 Apr;97(4):860-4
references: 16536788
references: PLoS Pathog. 2007 Apr;3(4):e60
references: 17465679
references: Cancer Res. 1992 Aug 1;52(15):4286-90
references: 1638541
references: Cell Mol Life Sci. 2006 Dec;63(24):2901-7
references: 17072502
references: Oncogene. 2008 Jan 7;27(2):218-24
references: 18176603
references: Br J Cancer. 2004 Aug 16;91(4):607-12
references: 15266312
references: Infect Immun. 2003 Aug;71(8):4238-49
references: 12874299
references: Eur Urol. 2011 Sep;60(3):493-500
references: 21664041
references: Immunotherapy. 2009 Mar;1(2):281-8
references: 20046960